Bodal Chemicals Limited — Investor Meet, 18-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Bodal Chemicals reported total revenue of ₹858 crores for the first half of FY25, representing a 27% year-on-year increase, driven mainly by higher volumes in dye intermediates, which surged 48%. EBITDA improved by 25% to ₹75 crores. However, the company's profitability faced challenges, with standalone profit after tax at ₹1.73 crores and a consolidated loss of ₹1.42 crores. For Q2 FY25, revenue was ₹428 crores with an EBITDA of ₹37 crores and a net profit of ₹0.59 crores.

2. Future Outlook and Growth Drivers: Management emphasized stability in global demand and pricing, despite geopolitical factors. Focused on enhancing capacity in the benzene derivatives segment, management anticipates increased contributions to revenue in Q4 FY25 and FY26, with plans to ramp up utilization rates post-approval from key industries.

3. Order Book and Operational Updates: The dye intermediates division achieved ₹327 crores in revenue during H1, with a positive outlook based on improved volume and pricing. The chlor-alkali division grew revenue by 20% year-on-year, driven by volume growth and anticipated demand recovery.

4. Analyst Q&A Insights: Analysts raised questions about persistent losses from inflationary pressures and the performance expectations for benzene derivatives. Management remains optimistic about stabilizing those losses. The benzene derivatives segment, currently producing 622 metric tons, is expected to reach 50% utilization in January, with revenue projections indicating significant growth as approval processes reach completion.

5. Market or Regulatory Updates: There was a mention of pending incentives from the Punjab government for the caustic soda business, with expectations of approval within months, reflecting management's confidence despite delays.

6. Strategic Focus Areas: The company aims to enhance its market position by diversifying into specialty chemicals, addressing operational challenges to improve overall margins. There is a strong emphasis on improving operational efficiency and product offerings.

7. Investor Insight: The financial performance, coupled with strategic enhancements and a recovery outlook, suggest a favorable potential for growth. With recovery in dye intermediates and expected advancements in benzene derivatives, this positions the stock favorably for investors looking for growth, suggesting a 'buy' position as confidence in management's strategic direction increases.